News & Views
HIPRA takes its sea bass vaccine to Turkish aquaculture market
Spanish veterinary pharmaceutical firm HIPRA's injectable vaccine against Vibriosis and Pasteurellosis is now available in the Turkish aquaculture market, a company press release has announced.
May 22, 2018 By Hatchery International staff
At the event announcing HIPRA ICTHIOVAC VR/PD vaccine's foray into the Turkish aquaculture market The ICTHIOVAC VR/PD vaccine, which is registered for sea bass, contains four different antigens (P. damselae subs. piscicida, L. anguillarum serotype O1, L. anguillarum serotype O2a, L. anguillarum serotype O2b) and AQUAMUN, HIPRA’s adjuvant for aquaculture. Conferring strong protection against Vibriosis and Pasteurellosis, the vaccine offers a combination of long-lasting immunity, reduced inflammatory reaction and less internal damage, HIPRA said.
The Turkey launch for the vaccine was held earlier this month at HIPRA’s headquarters attended by producers and fish health specialists from the major players in the Turkish aquaculture industry.
Participants were welcomed by Jordi Baborés, zone director EMEA & CIS at HIPRA, who highlighted the company’s distinctive values: quality, innovation and commitment, with animal health prevention as its main focus.
Gustavo Espelleta, an external consultant for HIPRA, spoke about how external environmental factors are influencing the evolution of the different pathologies affecting Mediterranean aquaculture, and the new challenges the industry will be facing in terms of diseases in the coming years.
Print this page
